Literature DB >> 16372033

Toxic effects of BZP-based herbal party pills in humans: a prospective study in Christchurch, New Zealand.

Paul Gee1, Sandra Richardson, Wolfram Woltersdorf, Grant Moore.   

Abstract

AIM: This study describes patterns of human toxicity related to the use of 1-benzylpiperazine (BZP)-based 'herbal party pills'.
METHODS: From 1 April 2005 to 1 September 2005 all presentations associated with party pill use were captured on a prospective data collection form.
RESULTS: There were 61 patients who presented on 80 occasions to the Emergency Department of Christchurch Hospital, New Zealand. Patients with adverse effects took an average of 4.5 tablets/capsules. Patients with mild to moderate toxicity experienced symptoms such as insomnia, anxiety, nausea, vomiting, palpitations, dystonia, and urinary retention. Some adverse reactions persisted up to 24 hours after ingestion. Fifteen toxic seizures were recorded. Two patients suffered life-threatening toxicity with status epilepticus and severe respiratory and metabolic acidosis.
CONCLUSIONS: Herbal party pills have been sold without regulation since 2000, and are now widely used by young New Zealanders. The principal ingredient of these pills is 1-benzylpiperazine (BZP). They appear to have a narrow safety margin when used recreationally by some humans, possibly because of intrinsic pharmacodynamic properties, self-dosing variability, or genetic polymorphism. Those with seizure disorders or coronary disease should avoid BZP as should those taking prescription sympathomimetics or anticholinergics. Coingestion with MDMA or amphetamine should also be cautioned against. The results of this study indicate that BZP can cause unpredictable and serious toxicity in some individuals. Furthermore, the results of this study should be carefully considered in any discussion on the legal status of piperazine-based party pills.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16372033

Source DB:  PubMed          Journal:  N Z Med J        ISSN: 0028-8446


  11 in total

Review 1.  Here today, gone tomorrow…and back again? A review of herbal marijuana alternatives (K2, Spice), synthetic cathinones (bath salts), kratom, Salvia divinorum, methoxetamine, and piperazines.

Authors:  Christopher D Rosenbaum; Stephanie P Carreiro; Kavita M Babu
Journal:  J Med Toxicol       Date:  2012-03

Review 2.  Pharmacology of stimulants prohibited by the World Anti-Doping Agency (WADA).

Authors:  J R Docherty
Journal:  Br J Pharmacol       Date:  2008-06       Impact factor: 8.739

3.  Neurogenic bladder and chronic urinary retention associated with MDMA abuse.

Authors:  John R Beuerle; Fermin Barrueto
Journal:  J Med Toxicol       Date:  2008-06

4.  Dissociative and sympathomimetic toxicity associated with recreational use of 1-(3-trifluoromethylphenyl) piperazine (TFMPP) and 1-benzylpiperzine (BZP).

Authors:  David M Wood; Jenny Button; Satnam Lidder; John Ramsey; David W Holt; Paul I Dargan
Journal:  J Med Toxicol       Date:  2008-12

Review 5.  Legal highs: staying on top of the flood of novel psychoactive substances.

Authors:  David Baumeister; Luis M Tojo; Derek K Tracy
Journal:  Ther Adv Psychopharmacol       Date:  2015-04

Review 6.  Nephrotoxic effects of designer drugs: synthetic is not better!

Authors:  Randy L Luciano; Mark A Perazella
Journal:  Nat Rev Nephrol       Date:  2014-03-25       Impact factor: 28.314

Review 7.  Sympathomimetic Toxidromes and Other Pharmacological Causes of Acute Hypertension.

Authors:  Andrew King; Mirjana Dimovska; Luke Bisoski
Journal:  Curr Hypertens Rep       Date:  2018-02-24       Impact factor: 5.369

8.  An In Vitro Study of the Neurotoxic Effects of N-Benzylpiperazine: A Designer Drug of Abuse.

Authors:  Karolina Persona; Anna Polus; Joanna Góralska; Anna Gruca; Aldona Dembińska-Kieć; Wojciech Piekoszewski
Journal:  Neurotox Res       Date:  2016-02-09       Impact factor: 3.911

9.  Highs and lows: patterns of use, positive and negative effects of benzylpiperazine-containing party pills (BZP-party pills) amongst young people in New Zealand.

Authors:  Rachael A Butler; Janie L Sheridan
Journal:  Harm Reduct J       Date:  2007-11-19

Review 10.  Designer drugs: mechanism of action and adverse effects.

Authors:  Dino Luethi; Matthias E Liechti
Journal:  Arch Toxicol       Date:  2020-04-06       Impact factor: 5.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.